Cover Image
市場調查報告書

異位性皮膚炎治療藥的全球市場的未來預測

GLOBAL ATOPIC DERMATITIS DRUGS MARKET FORECAST 2018-2026

出版商 Inkwood Research 商品編碼 626309
出版日期 內容資訊 英文 121 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
異位性皮膚炎治療藥的全球市場的未來預測 GLOBAL ATOPIC DERMATITIS DRUGS MARKET FORECAST 2018-2026
出版日期: 2018年04月16日 內容資訊: 英文 121 Pages
簡介

本報告提供全球異位性皮膚炎治療藥的市場未來展望相關分析,跟系統概要和市場結構,主要的推動及阻礙市場要素,整體市場規模趨勢預測 (今後9年份),各作用機制、各類藥物、各地區的詳細趨勢,相關產業的關聯結構與市場機會,市場競爭環境,主要企業簡介等調查。

第1章 分析範圍

第2章 分析方法

第3章 摘要整理

第4章 市場動態

  • 簡介:異位性皮膚炎
  • 市場定義和範圍
  • 法律上、政策上、規定上的課題
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 課題

第5章 各作用機制 (ROA) 的市場

  • 外用製劑
  • 口服藥
  • 注射藥

第6章 各類藥物的市場

  • 局部性抗生素
  • 局部性抗組織胺藥物
  • 局部性皮質類固醇
  • 局部性保濕劑/軟化劑
  • 局部性CALCINEURIN
  • 免疫調節藥物
  • 非適應症 (非標籤藥物) 療法
  • 全身性的醫藥品
  • PDE-4抑制劑
  • 白細胞介素抑制劑

第7章 主要分析指標

  • 波特的五力分析
  • 市場機會矩陣
  • 供應商環境
  • 開發平台分析

第7章 各地區分析

  • 北美 (美國,加拿大)
  • 歐洲 (德國,法國,英國,俄羅斯等)
  • 亞太地區 (印度,中國,日本,澳洲、紐西蘭,韓國等)
  • 其他的國家 (RoW:南美,中東、非洲)

第9章 企業簡介

  • ALLERGAN PLC.
  • AQUA PHARMACEUTICALS (ALMIRALL COMPANY的子公司)
  • Astellas Pharma Inc.
  • BAYER AG
  • BIOFRONTERA AG
  • BRISTOL-MYERS SQUIBB
  • STIEFEL LABORATORIES INC
  • ENCORE DERMATOLOGY
  • GALDERMA SA
  • LEO PHARMA
  • MEDA PHARMACEUTICALS (MYLAN)
  • NOVARTIS AG
  • PFIZER
  • REGENERON PHARMACEUTICALS
  • SANOFI SA
  • VALENT PHARMACEUTICAL INC.
目錄
Product Code: 16698

KEY FINDINGS

The Atopic Dermatitis Drugs global market is growing at 4.66% of CAGR over the forecasting years. Growing incidences of allergies due to particular foods is the major factor augmenting the market growth globally.

MARKET INSIGHTS

Atopic Dermatitis is a skin disease also known as chronic eczematous. The symptoms of this disease vary person to person. However, some of its common symptoms are inflamed and itchy skin that causes crackling, minute blisters, swelling, scaling, and crusting. The global Atopic Dermatitis drugs market comprise of two segments route of administration and drug class. The topical segment holds the highest share in the Atopic Dermatitis Drugs route of administration market. The interleukin inhibitor segment is anticipated to generate the highest revenue in the Atopic Dermatitis drug class market. The global Atopic Dermatitis Drugs market is highly generic which creates a lot of challenges in the growth of the market globally.

REGIONAL INSIGHTS

The Atopic Dermatitis Drugs market is segmented in four key geographies like North America, Europe, Asia Pacific, and rest of world. North America is the global leader in the Atopic Dermatitis Drugs market. Growing allergies is the key reasons for the growth of this market in the North American region. Europe Atopic Dermatitis Drugs market continues to escalate in terms of revenue majorly due to the rising awareness among the population. Atopic Dermatitis is highly prevalent in APAC region. It is the second largest Atopic Dermatitis Drugs market during the forecasting years. It is also the most common skin disease in the region, so the demand for the market is highest in APAC region.

COMPETITIVE INSIGHTS

The established players in the market are Allergan Plc., Aqua Pharmaceuticals (An Almirall Company), Astellas Pharma Inc., Bayer Ag, Biofrontera Ag, Bristol-Myers Squibb, Stiefel Laboratories Inc., Encore Dermatology, Galderma Sa, Leo Pharma, Meda Pharmaceuticals (Mylan), Novartis Ag, Pfizer, Regeneron Pharmaceuticals, Sanofi Sa, and Valent Pharmaceutical Inc.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. NORTH AMERICA HOLDS THE LARGEST CHUNK OF THE GLOBAL MARKET IN 2017
    • 3.2.2. TOPICAL SEGMENT HOLDS THE MAJORITY SHARE IN THE ROUTE OF ADMINISTRATION MARKET
    • 3.2.3. INTERLEUKIN INHIBITOR SEGMENT IS ANTICIPATED TO GENERATE THE HIGHEST REVENUE IN THE DRUG CLASS MARKET

4. MARKET DYNAMICS

  • 4.1. INTRODUCTION: ATOPIC DERMATITIS
  • 4.2. MARKET DEFINITION & SCOPE
  • 4.3. LEGAL, POLICY AND REGULATORY ISSUES
  • 4.4. MARKET DRIVERS
    • 4.4.1. GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
    • 4.4.2. GROWING FOCUS ON SYSTEMATIC THERAPIES
    • 4.4.3. INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
  • 4.5. MARKET RESTRAINTS
    • 4.5.1. STRINGENT REGULATIONS FOR PRODUCT APPROVAL
    • 4.5.2. GENERIC COMPETITION
  • 4.6. MARKET OPPORTUNITIES
    • 4.6.1. INCREASING M&A LEADING TO MARKET CONSOLIDATION
    • 4.6.2. LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
    • 4.6.3. GROWING FOCUS ON NOVEL DRUGS
  • 4.7. MARKET CHALLENGES
    • 4.7.1. BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
    • 4.7.2. HIGHLY GENERCIZED MARKET
    • 4.7.3. POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE

5. MARKET BY ROUTE OF ADMINISTRATION (ROA)

  • 5.1. TOPICAL
  • 5.2. ORAL
  • 5.3. INJECTABLE

6. MARKET BY DRUG CLASS

  • 6.1. TOPICAL ANTIBIOTICS
  • 6.2. TOPICAL ANTIHISTAMINES
  • 6.3. TOPICAL CORTICOSTEROIDS
  • 6.4. TOPICAL MOISTURIZERS/EMOLLIENTS
  • 6.5. TOPICAL CALCINEURIN INHIBITORS
  • 6.6. IMMUNOMODULATORS
  • 6.7. OFF-LABEL THERAPIES
  • 6.8. SYSTEMIC AGENTS
  • 6.9. PDE-4 INHIBITOR
  • 6.10. INTERLEUKIN INHIBITOR

7. KEY ANALYTICS

  • 7.1. PORTERS FIVE FORCE MODEL
    • 7.1.1. THREAT OF NEW ENTRANTS
    • 7.1.2. THREAT OF SUBSTITUTE
    • 7.1.3. BARGAINING POWER OF SUPPLIERS
    • 7.1.4. BARGAINING POWER OF BUYERS
    • 7.1.5. THREAT OF COMPETITIVE RIVALRY
  • 7.2. OPPORTUNITY MATRIX
  • 7.3. VENDOR LANDSCAPE
  • 7.4. PIPELINE ANALYSIS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. GERMANY
    • 8.2.2. FRANCE
    • 8.2.3. UNITED KINGDOM
    • 8.2.4. RUSSIA
    • 8.2.5. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. INDIA
    • 8.3.2. CHINA
    • 8.3.3. JAPAN
    • 8.3.4. AUSTRALIA AND NEW ZEALAND
    • 8.3.5. SOUTH KOREA
    • 8.3.6. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. LATIN AMERICA
    • 8.4.2. MIDDLE EAST AND AFRICA

9. COMPANY PROFILES

  • 9.1. ALLERGAN PLC.
  • 9.2. AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
  • 9.3. ASTELLAS PHARMA INC.
  • 9.4. BAYER AG
  • 9.5. BIOFRONTERA AG
  • 9.6. BRISTOL-MYERS SQUIBB
  • 9.7. STIEFEL LABORATORIES INC
  • 9.8. ENCORE DERMATOLOGY
  • 9.9. GALDERMA SA
  • 9.10. LEO PHARMA
  • 9.11. MEDA PHARMACEUTICALS (MYLAN)
  • 9.12. NOVARTIS AG
  • 9.13. PFIZER
  • 9.14. REGENERON PHARMACEUTICALS
  • 9.15. SANOFI SA
  • 9.16. VALENT PHARMACEUTICAL INC.

LIST OF TABLES

  • TABLE 1: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ MILLION)
  • TABLE 2: REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET
  • TABLE 3: RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
  • TABLE 4: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY ROA, 2018-2026, (IN $ MILLION)
  • TABLE 5: GLOBAL TOPICAL ATOPIC DERMATITIS DRUGS MARKET, BY REGION, 2018-2026 (IN $ MILLION)
  • TABLE 6: GLOBAL ORAL ATOPIC DERMATITIS DRUGS MARKET, BY REGION, 2018-2026 (IN $ MILLION)
  • TABLE 7: GLOBAL INJECTABLE ATOPIC DERMATITIS DRUGS MARKET, BY REGION, 2018-2026 (IN $ MILLION)
  • TABLE 8: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY DRUG CLASS, 2018-2026 (IN $ MILLION)
  • TABLE 9: OPPORTUNITY MATRIX FOR DIABETES DRUGS MARKET
  • TABLE 10: VENDOR LANDSCAPE OF DIABETES DRUGS MARKET
  • TABLE 11: PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
  • TABLE 12: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY GEOGRAPHY, 2018-2026, (IN $ MILLION)
  • TABLE 13: NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)
  • TABLE 14: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)
  • TABLE 15 ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)
  • TABLE 16: REST OF THE WORLD ATOPIC DERMATITIS DRUGS MARKET, BY REGION, 2018-2026 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: GLOBAL ATOPIC DERMATITIS DRUGS MARKET 2018-2026 (IN $ MILLION)
  • FIGURE 2: NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 3: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL ROUTE OF ADMINISTRATION, 2018-2026 (IN $ MILLION)
  • FIGURE 4: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY INTERLEUKIN INHIBITOR, 2018-2026 (IN $ MILLION)
  • FIGURE 5: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY ROA, 2017 & 2026 (IN %)
  • FIGURE 6: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL, 2018-2026 (IN $ MILLION)
  • FIGURE 7: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY ORAL, 2018-2026 (IN $ MILLION)
  • FIGURE 8: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY INJECTABLE, 2018-2026 (IN $ MILLION)
  • FIGURE 9: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY DRUG CLASS, 2017 & 2026 (IN %)
  • FIGURE 10: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL ANTIBIOTICS, 2018-2026 (IN $ MILLION)
  • FIGURE 11: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL ANTIHISTAMINES, 2018-2026 (IN $ MILLION)
  • FIGURE 12: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL CORTICOSTEROIDS, 2018-2026 (IN $ MILLION)
  • FIGURE 13: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL MOISTURIZERS/EMOLLIENTS, 2018-2026 (IN $ MILLION)
  • FIGURE 14: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL CALCINEURIN INHIBITORS, 2018-2026 (IN $ MILLION)
  • FIGURE 15: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY IMMUNOMODULATORS, 2018-2026 (IN $ MILLION)
  • FIGURE 16: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY OFF-LABEL THERAPIES, 2018-2026 (IN $ MILLION)
  • FIGURE 17: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY SYSTEMIC AGENTS, 2018-2026 (IN $ MILLION)
  • FIGURE 18: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY PDE-4 INHIBITOR, 2018-2026 (IN $ MILLION)
  • FIGURE 19: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY INTERLEUKIN INHIBITOR, 2018-2026 (IN $ MILLION)
  • FIGURE 20: PORTER'S FIVE FORCE MODEL OF DIABETES DRUGS MARKET
  • FIGURE 21: GLOBAL ATOPIC DERMATITIS DRUGS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
  • FIGURE 22: NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET, 2017 & 2026 (IN %)
  • FIGURE 23: UNITED STATES ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 24: CANADA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 25: EUROPE ATOPIC DERMATITIS DRUGS MARKET, 2017 & 2026 (IN %)
  • FIGURE 26: GERMANY ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 27: FRANCE ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 28: UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 29: RUSSIA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 30: REST OF EUROPE ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 31: ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET, 2017 & 2026 (IN %)
  • FIGURE 32: INDIA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 33: JAPAN ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 34: AUSTRALIA AND NEW ZEALAND ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 35: SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 36: REST OF ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 37: LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 38: MIDDLE EAST AND AFRICA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
Back to Top